CLN6 antibody (C-Term)
Quick Overview for CLN6 antibody (C-Term) (ABIN634889)
Target
See all CLN6 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term
-
Specificity
- CLN6 antibody was raised against the C terminal of CLN6
-
Purification
- Affinity purified
-
Immunogen
- CLN6 antibody was raised using the C terminal of CLN6 corresponding to a region with amino acids RLFLDSNGLFLFSSFALTLLLVALWVAWLWNDPVLRKKYPGVIYVPEPWA
-
-
-
-
Application Notes
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Comment
-
CLN6 Blocking Peptide, (ABIN5612933), is also available for use as a blocking control in assays to test for specificity of this CLN6 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of CLN6 antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Handling Advice
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- CLN6 (Ceroid-Lipofuscinosis, Neuronal 6, Late Infantile, Variant (CLN6))
-
Alternative Name
- CLN6
-
Background
- CLN6 is one of eight which have been associated with neuronal ceroid lipofuscinoses (NCL). Also referred to as Batten disease, NCL comprises a class of autosomal recessive, neurodegenerative disorders affecting children. The genes responsible likely CLN6 involved in the degradation of post-translationally modified proteins in lysosomes. The primary defect in NCL disorders is thought to be associated with lysosomal storage function.
-
Molecular Weight
- 36 kDa (MW of target protein)
-
Pathways
- Glycosaminoglycan Metabolic Process
Target
-